NCT05613140

Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure

Name: Clinical Trial NCT05613140
Creator: Novartis Pharmaceuticals
Keywords: Chronic Heart Failure, sacubitril/valsartan, drug, clinical trial, United States of America

A Pre-post Analysis of Healthcare Resource Utilization and Costs of Care in a New User Cohort of Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure

Novartis Pharmaceuticals·ClinicalTrials.gov·drugCompleted

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Chronic Heart Failure
Drug/Device/Intervention: sacubitril/valsartan
Study type: Observational
Intervention type: drug

Sponsor & location

Primary sponsor: Novartis Pharmaceuticals
Funder: Novartis
Location: East Hanover, United States of America

Timeline & enrollment

Phase: N/A
Start date: Aug 02, 2021
End date: Nov 05, 2021
Enrollment: 9230 participants

Primary outcome

Mean number of Heart Failure - specific hospitalizations of adult HFrEF patients treated with sacubitril/valsartan

Summary

This study evaluated changes in healthcare resource utilization (HCRU) and costs of care within 12 months following initiation of sacubitril/valsartan (sac/val) in commercially insured and Medicare Advantage (MA) lives in the U.S among adult patients with heart failure with reduced ejection fraction (HFrEF) (cohort 1) and adult patients with chronic heart failure (CHF) (cohort 2).

ICD-10 classifications

Heart failureHeart failure, unspecifiedCongestive heart failureHypertensive heart disease with (congestive) heart failureHypertensive heart disease without (congestive) heart failure

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05613140
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05613140 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharmaceuticals and is currently Completed. The study focuses on Chronic Heart Failure. Target enrollment is 9230 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.